Pfizer awarded $1.35B Army contract modification for vaccine BNT162b2 production » 17:5107/2307/23/21
Pfizer was awarded a…
Pfizer was awarded a $1.35B modification to a contract for the production of vaccine BNT162b2. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of March 31, 2022. U.S. Army Contracting Command is the contracting activity.
Glaxo begins shipping influenza vaccine supply for 2021-2022 U.S. season » 13:3907/2307/23/21
GSK announced it started…
GSK announced it started shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2021-22 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration's Center for Biologics Evaluation and Research, the company said in a statement. GSK expects to distribute more doses than it has in any previous influenza season, with a record supply of more than 50 million doses of its influenza vaccine for the 2021-2022 season to the US market. "The flu remains a serious and unpredictable disease that can result in mild to severe illness. As more people are vaccinated against COVID-19 and we return to more normal, social activities, it is important that anyone over the age of 6 months is vaccinated against the flu," GSK said.
AbbVie announces FDA approval of Dalvance for bacterial skin infection » 12:5207/2307/23/21
AbbVie announced that the…
AbbVie announced that the Food and Drug Administration approved Dalvance for the treatment of acute bacterial skin and skin structure infection in pediatric patients from birth. Dalvance is the first single-dose option administered as a 30-minute intravenous infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant staphylococcus aureus, the company said in a statement.
Arvinas price target raised to $111 from $101 at BMO Capital » 09:3307/2307/23/21
BMO Capital analyst…
BMO Capital analyst Matthew Luchini raised the firm's price target on Arvinas (ARVN) to $111 from $101 and keeps an Outperform rating on the shares. The analyst cites the company's global collaboration deal with Pfizer (PFE), which he calls a "solid partner" given its deep global development and commercialization expertise plus leading breast cancer franchise in Ibrance.
Pfizer, BioNTech to supply U.S. with additional 200M doses of Covid-19 vaccine » 06:4607/2307/23/21
Pfizer (PFE) and BioNTech…
Pfizer (PFE) and BioNTech SE (BNTX) announced that the U.S. government has purchased an additional 200M doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected to be delivered from October 2021 through April 2022. This brings the total number of doses to be supplied by the companies to the U.S. government under its existing supply agreement to 500M. In a separate announcement on June 10, 2021, Pfizer and BioNTech shared plans to provide the U.S. government with 500M doses of the companies' COVID-19 vaccine for donation to the world's poorest nations. The companies expect to deliver 110M of the additional doses by December 31, 2021, with the remaining 90M doses to be delivered no later than April 30, 2022. The U.S. government also has the option to acquire an updated version of the vaccine to address potential variants as well as new formulations of the vaccine, if available and authorized.
Arvinas price target raised to $153 from $118 at Citi » 06:2607/2307/23/21
Citi analyst Yigal…
Citi analyst Yigal Nochomovitz raised the firm's price target on Arvinas (ARVN) to $153 from $118 and keeps a Buy rating on the shares. The Pfizer (PFE) deal is "transformational" for Arvinas as it lends validation to the PROTAC platform, substantially accelerates development efforts for ARV-471, and meaningfully strengthens the financial health of the company, Nochomovitz tells investors in a research note.
Vaccine panel expresses preliminary support for Covid boosters, WSJ reports » 06:0807/2307/23/21
JNJ, PFE, BNTX, MRNA
The Advisory Committee on…
The Advisory Committee on Immunization Practices panel, A U.S. advisory panel on vaccines which advises the U.S. Centers for Disease Control and Prevention, expressed preliminary support for giving Covid-19 boosters to the immunocompromised, and endorsed continued use of the Johnson & Johnson vaccine despite a recent health-risk warning, The Wall Street Journal's Jared S. Hopkins and Felicia Schwartz report. Reference Link
Arvinas price target raised to $108 from $100 at Oppenheimer » 04:5407/2307/23/21
Oppenheimer analyst Mark…
Oppenheimer analyst Mark Breidenbach raised the firm's price target on Arvinas (ARVN) to $108 from $100 and reiterates an Outperform rating on the shares after the company and Pfizer (PFE) announced a global collaboration to accelerate development and commercialization of ARV-471. The analyst believes non-public clinical data "may have helped entice" Pfizer, which he sees as an "ideal partner with a well-established commercial footprint in the breast cancer space."
Siemens Healthineers initiated with a Buy at Societe Generale » 18:1607/2207/22/21
Societe Generale analyst…
Societe Generale analyst Delphine Le Louet initiated coverage of Siemens Healthineers with a Buy rating and EUR 61.70 price target. The analyst said that the Buy rating is underpinned by the company's structurally growing end-markets; the innovation driving its growth in an expanding market; its market leading positions and potential for margin improvement; and the Varian integration.
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital » 12:5207/2207/22/21
Roth Capital analyst…
Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Arvinas (ARVN) with a $120 price target after the company announced a development and collaboration agreement with Pfizer (PFE) for ARV-471. The agreement "appears more substantial" than the original 2018 discovery and development agreement between Arvinas and Pfizer, Jallah tells investors in a research note. The analyst views the new agreement, which includes a $650M upfront payment for exclusive rights to a single early-stage asset, as "perhaps strong validation of the derisking of the platform that has occurred." Additionally, Pfizer's investment of $350M for a 7% equity stake, at a 30% premium, is further evidence of its "growing confidence in the platform," says Jallah, who "would not be surprised to see a broadening of this partnership."